Immunotherapy for renal cell cancer in the era of targeted therapy.
about
Sunitinib in solid tumorsImmunotherapy for metastatic renal cell carcinoma.Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.Anti-Inflammatory Agents for Cancer Therapy.JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.Forkhead box J1 expression is upregulated and correlated with prognosis in patients with clear cell renal cell carcinoma.Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinomaTargeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinomaImmunotherapy of genitourinary malignancies.Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytesAn oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe?Targeted therapies for renal cell carcinoma: more gains from using them again.
P2860
Q28245467-56A772A4-8F22-45B4-A4D6-5B20D5F6B32DQ30234458-716B700F-B2C4-4B89-B2F9-185C3935F474Q33680566-AE045D77-F909-4C0A-B737-7AEAE7DDC92DQ33744129-10F2FBCF-316F-43C7-9704-64DF909DF156Q33747097-4605A30E-A7BF-4DC4-B64B-F0CDA5441F28Q34503610-09AB0F38-0ADF-464D-B328-728C5FB7FC60Q34995745-05681A45-F40A-409F-8CF0-CD5A88CB954AQ35681948-9C17E388-D8AD-4341-8395-C1B41A0A2B91Q35865051-7EF010C8-1263-444B-92E0-35C0A607D92BQ39874482-1C439E6D-55AA-4088-8810-DD5934FCE2A4Q39920448-6AF0E248-701D-4931-9F49-D7AABA89DE94Q41898172-2CA3CE1C-5876-4D2C-86E8-046D5A198699Q43006494-C06FB36A-E397-4FED-A48C-DDBE59262A96Q43121227-0E37416A-A383-4F00-8FD7-AB8909BEA810
P2860
Immunotherapy for renal cell cancer in the era of targeted therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunotherapy for renal cell cancer in the era of targeted therapy.
@en
Immunotherapy for renal cell cancer in the era of targeted therapy.
@nl
type
label
Immunotherapy for renal cell cancer in the era of targeted therapy.
@en
Immunotherapy for renal cell cancer in the era of targeted therapy.
@nl
prefLabel
Immunotherapy for renal cell cancer in the era of targeted therapy.
@en
Immunotherapy for renal cell cancer in the era of targeted therapy.
@nl
P2860
P356
P1476
Immunotherapy for renal cell cancer in the era of targeted therapy.
@en
P2093
Chris Coppin
P2860
P304
P356
10.1586/14737140.8.6.907
P577
2008-06-01T00:00:00Z